Flu Vaccines
Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
Published in Vaccine Weekly, May 28th, 2008
Novavax, Inc. (NASDAQ:NVAX) announced that it has completed enrollment in the Phase I/IIa study of its pandemic influenza vaccine including a total of approximately 230 subjects. Favorable interim results from the first phase of the study, which included dose-escalation in 70 healthy adult volunteers, were reported in December 2007. The interim findings suggested that the vaccine is well tolerated and immunogenic at the 15 microgram and 45 microgram dose levels. Based upon its review of these results, the Data and Safety Monitoring Board (DSMB) recommended that the study continue.
Enrollment has now been completed in the second phase of the trial, which includes...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2008-05-28)
More Articles from Vaccine Weekly
- DOE/Brookhaven National Laboratory
Scientists determine drug target for the most potent botulinum neurotoxin - Emory University
Researchers find first conclusive evidence of Alzheimer's-like brain tangles in nonhuman primates - Anthrax
Studies from Harvard University, Medical Department update current data on anthrax - Cancer Gene Therapy
Research in the area of cancer gene therapy reported from M.E. Mossoba and colleagues - Human Papillomavirus Vaccines
New findings reported from Florida State University, Medical Department describe advances in human papillomavirus vaccines - Immunization
New immunization research has been reported by scientists at University of Ottawa - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
